Pharmacosmos A/S: Anemia trials

The registry lists 14 Anemia studies with Pharmacosmos A/S as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 1 2Phase 3 10No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency AnaemiaCompletedNCT03238911Phase 3Results posted
• Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency AnaemiaCompletedNCT03237065Phase 3Results posted
• An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)CompletedNCT02962648Phase 3Results posted
• Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)CompletedNCT02940886Phase 3Results posted
• Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney DiseaseCompletedNCT02940860Phase 3Results posted
• IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron SucroseCompletedNCT02130063Phase 3Results posted
• A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)CompletedNCT01145638Phase 3Results posted
• Iron Isomaltoside 1000 (Monofer®) in Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related AnaemiaCompletedNCT01102413Phase 3Results posted
• Dose-escalation Trial of the Safety, Pharmacokinetics, and Pharmacodynamics of Iron Isomaltoside (Monofer®)CompletedNCT03013439Phase 1
• Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With The Intravenous Iron (Monofer®)CompletedNCT02546154
• A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against PlaceboWithdrawnNCT02172001Phase 3
• Time to Relapse of Iron Deficiency Anemia After Standard Treatment With a New Intravenous Iron (Monofer®)CompletedNCT01900197
• Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced AnaemiaCompletedNCT01280240Phase 1
• Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency AnaemiaCompletedNCT01017614Phase 3